Product
Siplizumab
5 clinical trials
14 indications
Indication
Hidradenitis SuppurativaIndication
Kidney FailureIndication
Kidney TransplantIndication
ChimeraIndication
AnaemiaIndication
Sickle CellIndication
Type 1 Diabetes MellitusIndication
Autoimmune Liver DiseaseIndication
Liver TransplantationIndication
Autoimmune HepatitisIndication
Primary Sclerosing CholangitisIndication
End Stage Liver DiseaseIndication
CirrhosisIndication
LiverClinical trial
An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis SuppurativaStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
Delayed Tolerance Through Mixed ChimerismStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Siplizumab-based Conditioning for Hematopoietic Stem Cell Transplantation in Patients With Advanced Sickle Cell Disease (CD2 SCD)Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
A T Cell Phenotype Signature Driven Dose Finding Study With Siplizumab in Type 1 Diabetes Mellitus (ITN095AI)Status: Active (not recruiting), Estimated PCD: 2026-12-31
Clinical trial
A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)Status: Not yet recruiting, Estimated PCD: 2025-12-31